GSK and CureVac announced JV to develop next generation mRNA COVID-19 vaccines
On Feb. 2, 2021, GlaxoSmithKline and CureVac announced a new ï¾€150m collaboration, building on their existing relationship, to…
Mateon announced completion of ARTI-19 and publication of positive interim data
On Feb. 2, 2021, Mateon Therapeutics announced that its ARTI-19 trial, evaluating ARTIVeda / PulmoHeal against COVID-19 in…
Novavax announced MOU to produce COVID-19 vaccine made in Canada
On Feb. 2, 2021, Novavax announced a memorandum of understanding (MOU) with the Canadian government to produce NVX-CoV2373,…
Clover and Dynavax announced planned global phase 2/3 efficacy trial of adjuvanted COVID-19 vaccine candidate
On Feb. 1, 2021, Clover Biopharmaceuticals and Dynavax Technologies announced a plan to initiate a global Phase 2/3…
Dynavax and CEPI announced $99 million in funding for CpG 1018 adjuvant manufacturing
On Feb. 1, 2021, Dynavax Technologies and the Coalition for Epidemic Preparedness Innovations (CEPI) announced they have entered…
Pfizer and BioNTech publish preclinical data from investigational COVID-19 vaccine program in Nature
On Feb. 1, 2021, Pfizer and BioNTech announced that preclinical data in non-human primate and mouse models from…
Sorrento announced the fourth patient was released from hospital following third infusion of stem cells
On Jan. 31, 2021, Sorrento Therapeutics announced additional positive results from its Phase 1b study of human allogeneic…
The CDC required wearing of face masks while on public transportation and at transportation hubs
On Jan. 30, 2021, as the COVID-19 pandemic continued to surge in the U.S., the CDC implemented a…
Rigel awarded $165 Million from US DOD for phase 3 clinical trial of Fostamatinib in COVID-19 patients
On Jan. 29, 2021, Rigel Pharma announced it has been awarded $16.5 million by the U.S. Department of…
Humanigen completed enrollment in phase 3 study of lenzilumab in hospitalized patients with COVID-19
On Jan. 29, 2021, Humanigen announced it had completed enrollment for its pivotal phase 3 study of lenzilumab…
Innovation Pharmaï¾’s phase 2 clinical trial of Brilacidin for treating COVID-19 began
On Jan. 29, 2021, Innovation Pharmaceuticals announced that the companyï¾’s Phase 2 clinical trial of Brilacidin for treating…
Single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of phase 3 ENSEMBLE trial
On Jan. 29, 2021, Johnson & Johnson announced topline efficacy and safety data from the Phase 3 ENSEMBLE…
Pfizer and BioNTech published data on COVID-19 vaccine-induced antibodiesï¾’ ability to neutralize SARS-CoV-2 UK strain
On Jan. 29, 2021, Pfizer and BioNTech announced that data from an in vitro study on the capability…
DNA Genotekﾒs OMNIgeneﾮﾷORAL included in EUA granted to Ambry Genetics for use in COVID-19 RT-PCR saliva test
On Jan. 29, 2021, OraSure Technologies announced its OMNIgeneﾮﾷORAL (OM-505) saliva collection kit, a product of subsidiary DNA…
COVID-19 | Diagnostics | Disease | Life Science News | NIH | Women's Health
Severe COVID-19 in pregnancy associated with preterm birth, other complications
On Jan. 28, 2021, National Institutes of Health (NIH) researchers reported that pregnant women who experienced severe symptoms…
New COVID-19 variants fueling Africa’s second wave
On Jan. 28, 2021, The WHO announced that COVID-19 cases and deaths were surging in Africa as more…
Precipio launched COVID-19 antibody testing at point-of-care
On Jan. 28, 2021, Precipio announced that following receipt of an Emergency Use Authorization from the U.S. Food…
Novavax COVID-19 vaccine demonstrated 89.3% efficacy in UK phase 3 trial
On Jan. 28, 2021, Novavax announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, had met the primary endpoint,…
DNA Genotekﾒs OMNIgeneﾮﾷORAL saliva collection device received Health Canada Authorization for COVID-19 testing
On Jan. 28, 2021, OraSure Technologies announced its OMNIgeneﾮﾷORAL (OME-505) saliva collection device, a product of Ottawa-based subsidiary…
Ajinomoto Bio-Pharma and Humanigen expanded agreement to support fill finish for COVID-19 therapeutic
On Jan. 27, 2021, Ajinomoto Bio-Pharma Services and Humanigen announced the companies will be expanding their manufacturing agreement…
OncoSec announced first subjects dosed in phase 1 trial of CORVax12, COVID-19 vaccine candidate
On Jan. 27, 2021, OncoSec Medical announced that it had dosed several subjects in its Phase 1 clinical…
Lilly, Vir Biotechnology and GSK announced first patient dosed in expanded BLAZE-4 trial for COVID-19
On Jan. 27, 2021, Eli Lilly, Vir Biotechnology and GlaxoSmithKline announced a collaboration to evaluate a combination of…
Moderna confirms discussions with US Government for additional 100 million doses of COVID-19 vaccine
On Jan. 27, 2021, Moderna confirmed that the Company is in discussion with the U.S. government to purchase…
Heat Biologics announced publication of additional preclinical COVID-19 vaccine results
On Jan. 27, 2021, Heat Biologics announced the publication of additional preclinical COVID-19 results in Frontiers in Immunology,…
In vitro studies demonstrated COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 with UK and South African Variants
On Jan. 27, 2021, Pfizer and BioNTech announced results from in vitro neutralization studies of sera from individuals…
Abbott’s panbio rapid antigen test received CE Mark for asymptomatic screening and sample collection
On Jan. 26, 2021, Abbott announced it had received CE Mark for two new uses of its Panbioï¾™…
NIH launched database to track neurological symptoms associated with COVID-19
On Jan. 26, 2021, NIH researchers announced that a new database to collect information from clinicians about COVID-19-related…
WHO recommended follow-up care, low-dose anticoagulants for COVID-19 patients
On Jan. 26, 2021, WHO recommends that patients who have COVID-19 – both confirmed and suspected – should…
Vaxart announced additional preclinical COVID-19 oral vaccine data and publication
On Jan. 26, 2021, Vaxart announced additional results from its SARS-CoV-2 Hamster Challenge Study, as well as a…
Sorrento announced positive preliminary results of phase 1b study of COVI-MSC for treatment of ICU COVID-19 patients
On Jan. 26, 2021, Sorrento Therapeutics announced positive preliminary results from its Phase 1b study of human allogeneic…